Abstract
PURPOSE: The aim of this study is to investigate the role of health-related quality-of-life (QoL) data in relative effectiveness assessments (REAs) of new anti-cancer drugs across European jurisdictions, during health technology assessment procedures.
METHODS: Comparative analysis of guidelines and publicly available REAs in six European jurisdictions of anti-cancer drugs approved by EMA between 2011 and 2013.
RESULTS: Fourteen anti-cancer drugs were included, adding up to 79 REAs. Whilst all guidelines state that QoL is a relevant endpoint to determine the relative effectiveness of new cancer drugs, QoL data were included in only 54% of the 79 reports and their impact on the recommendations was limited.
CONCLUSIONS: Whilst national guidelines recognize the relevance of QoL to determine the relative effectiveness of new anti-cancer drugs, this is not well-reflected in current assessments. Developing and implementing into REAs specific evidence requirements for QoL data would improve the use of this patient-centred outcome in future reimbursement and pricing decisions.
| Original language | English |
|---|---|
| Pages (from-to) | 2479-2488 |
| Journal | Quality of Life Research |
| Volume | 26 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sept 2017 |
Keywords
- Comparative effectiveness
- Quality of life
- Health technology assessment
- Reimbursement
- Antineoplastic agents
- Patient-centred outcome research
